News in English
Декабрь
2024
22
23
24
25
26
27
28
29
30
31

Новости за 20.12.2024

Splice Today 

We'll Call Him Vladimir

One time, I was thrown into contact with a dangerous man. We’ll call him Vladimir. I didn’t know he was dangerous because he was presented as normal. I was young at the time and took everything at face value. When I first met him, he was hiding under the basement steps in his mother’s house with some cats, smoking pot. I was told this was a habit of his and not to pay any attention to it, he was just shy around strangers.

Читать дальше...

Timesofindia.indiatimes.com (sports) 

Eijaz Khan reacts to ex-girlfriend Pavitra Punia's comment on him being a 'narcissist'

Eijaz Khan and Pavitra Punia's relationship drama continues following their recent split. Pavitra hinted at Eijaz's narcissistic traits while discussing their breakup, prompting a response from Eijaz. He emphasized his reluctance to discuss personal matters publicly. Rumors of religious differences as a factor in their separation were also addressed, with both Pavitra and Eijaz's spokesperson denying such claims.

IntelliNews.com 

Russia’s CBR keeps key rate at 21% under pressure

In a surprise decision CBR governor Elvia Nabiullina kept interest rates on hold at 21% as she comes under mounting pressure from Russian President Vladimir Putin and the oligarchs who accuse her of destroying the economy.

Top Stories (us) - Google News (ru) 

Novo Nordisk shares plunge 20% after disappointing trial results; Lilly jumps - CNBC

  1. Novo Nordisk shares plunge 20% after disappointing trial results; Lilly jumps  CNBC
  2. What Novo Nordisk’s disappointing trial results mean for the obesity drug market  STAT
  3. 'A worst case scenario for Novo': Read the market reaction to CagriSema trial  Reuters.com
  4. There’s a New Obesity King  The Wall Street Journal

Google.com 

Novo Nordisk shares plunge 19% after disappointing trial results; Lilly jumps in premarket - CNBC

  1. Novo Nordisk shares plunge 19% after disappointing trial results; Lilly jumps in premarket  CNBC
  2. Novo Nordisk’s next-generation weight-loss drug matches Lilly’s Zepbound in major trial, but doesn’t surpass it  CNN
  3. Novo Nordisk Dives On CagriSegma Obesity Drug Trial. Eli Lilly, Viking Jump.  Investor's Business Daily
  4. Novo Nordisk Falls Most on Record After New Weight Drug Disappoints  Bloomberg